上海医药(601607.SH)：控股股东上实集团拟增持5500万股至7400万股公司H股股份

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its controlling shareholder, Shanghai Shibei Group, plans to increase its holdings of the company's H-shares by 55 million to 74 million shares within the next 12 months, representing up to 2% of the company's voting shares [1] Group 1 - The increase in shareholding will be executed through Shanghai Shibei Group's wholly-owned subsidiary, Shanghai Shibei International, via the Hong Kong Stock Exchange's centralized bidding system [1] - The share purchase will not have a fixed price range and will be conducted based on market conditions [1] - The funding for this share acquisition will come from Shanghai Shibei International's own funds [1]